Literature DB >> 6413994

Adverse effects of anticholinergic medication on positive schizophrenic symptoms.

E C Johnstone, T J Crow, I N Ferrier, C D Frith, D G Owens, R C Bourne, S J Gamble.   

Abstract

In a series of 36 patients with acute schizophrenia flupenthixol dosage was blindly adjusted to give a fixed level of sedation. Patients were than randomly allocated to procyclidine or placebo. The patients receiving procyclidine experienced more positive schizophrenic symptoms and less severe extrapyramidal features by comparison with placebo patients. Blood levels of prolactin and flupenthixol estimated by radioimmunoassay were not significantly changed by the addition of procyclidine. Flupenthixol dosage and levels and prolactin levels were significantly related. There was no significant association between clinical and laboratory measures, with the exception that a curvilinear (inverted U) relationship was demonstrated between flupenthixol levels and antipsychotic and extrapyramidal effects. This relationship may be due to the fact that, in a study of this design, patients resistant to the effects of neuroleptic medication are likely to be given the highest doses. The findings support earlier claims that anticholinergic medication has adverse effects on schizophrenic symptoms.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6413994     DOI: 10.1017/s0033291700047942

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  20 in total

Review 1.  Managing antipsychotic-induced parkinsonism.

Authors:  D C Mamo; R A Sweet; M S Keshavan
Journal:  Drug Saf       Date:  1999-03       Impact factor: 5.606

2.  Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol.

Authors:  A L Nordström; L Farde; C Halldin
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 3.  Pharmacological treatment of patients with schizophrenia. Past and present problems and potential future therapy.

Authors:  D A Johnson
Journal:  Drugs       Date:  1990-04       Impact factor: 9.546

4.  Problems in monitoring needs for care of long term psychiatric patients: evaluating a service for casual attenders.

Authors:  S Compton; T Brugha
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1988-04       Impact factor: 4.328

Review 5.  Antipsychotic drugs. Clinical pharmacokinetics of potential candidates for plasma concentration monitoring.

Authors:  A E Balant-Gorgia; L Balant
Journal:  Clin Pharmacokinet       Date:  1987-08       Impact factor: 6.447

6.  Cholinergic modulation of auditory processing, sensory gating and novelty detection in human participants.

Authors:  Inge Klinkenberg; Arjan Blokland; Wim J Riedel; Anke Sambeth
Journal:  Psychopharmacology (Berl)       Date:  2012-10-03       Impact factor: 4.530

7.  Interaction study between remoxipride and biperiden.

Authors:  W Yisak; L Farde; C von Bahr; L B Nilsson; G Fredriksson; S Ogenstad
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

8.  Clozapine's functional mesolimbic selectivity is not duplicated by the addition of anticholinergic action to haloperidol: a brain stimulation study in the rat.

Authors:  E L Gardner; L S Walker; W Paredes
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

9.  Prevention of haloperidol-induced alterations in brain acetylcholinesterase activity by vitamins B co-administration in a rodent model of tardive dyskinesia.

Authors:  Gersilene Valente de Oliveira; Patrícia Xavier Lima Gomes; Fernanda Yvelize Ramos de Araújo; Silvânia Maria Mendes Vasconcelos; Hélio Vitoriano Nobre Júnior; Francisca Cléa Florenço de Sousa; David F de Lucena; Thomas N Hyphantis; André Férrer Carvalho; Danielle Silveira Macêdo
Journal:  Metab Brain Dis       Date:  2012-10-25       Impact factor: 3.584

10.  Modulation of prepulse inhibition through both M(1) and M (4) muscarinic receptors in mice.

Authors:  Morgane Thomsen; Jürgen Wess; Brian S Fulton; Anders Fink-Jensen; S Barak Caine
Journal:  Psychopharmacology (Berl)       Date:  2009-12-15       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.